DE1210126B - Verfahren zur Stabilisierung von langwirkenden Suspensionen von adrenokortikotropem Hormon (ACTH) - Google Patents
Verfahren zur Stabilisierung von langwirkenden Suspensionen von adrenokortikotropem Hormon (ACTH)Info
- Publication number
- DE1210126B DE1210126B DEN21945A DEN0021945A DE1210126B DE 1210126 B DE1210126 B DE 1210126B DE N21945 A DEN21945 A DE N21945A DE N0021945 A DEN0021945 A DE N0021945A DE 1210126 B DE1210126 B DE 1210126B
- Authority
- DE
- Germany
- Prior art keywords
- acth
- zinc
- phosphate
- suspensions
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 title claims description 23
- 229960000258 corticotropin Drugs 0.000 title claims description 23
- 239000000725 suspension Substances 0.000 title description 28
- 101800000414 Corticotropin Proteins 0.000 title description 22
- 102100027467 Pro-opiomelanocortin Human genes 0.000 title description 22
- 238000000034 method Methods 0.000 title description 5
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 title description 3
- 230000000087 stabilizing effect Effects 0.000 title 1
- 238000002360 preparation method Methods 0.000 claims description 25
- 239000011701 zinc Substances 0.000 claims description 16
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 12
- 229910052725 zinc Inorganic materials 0.000 claims description 12
- UGZADUVQMDAIAO-UHFFFAOYSA-L zinc hydroxide Chemical compound [OH-].[OH-].[Zn+2] UGZADUVQMDAIAO-UHFFFAOYSA-L 0.000 claims description 9
- 229910021511 zinc hydroxide Inorganic materials 0.000 claims description 9
- 229940007718 zinc hydroxide Drugs 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 6
- 229910001392 phosphorus oxide Inorganic materials 0.000 claims description 5
- VSAISIQCTGDGPU-UHFFFAOYSA-N tetraphosphorus hexaoxide Chemical compound O1P(O2)OP3OP1OP2O3 VSAISIQCTGDGPU-UHFFFAOYSA-N 0.000 claims description 5
- 239000007900 aqueous suspension Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 claims 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 24
- 229910019142 PO4 Inorganic materials 0.000 description 14
- 235000021317 phosphate Nutrition 0.000 description 14
- 229960005070 ascorbic acid Drugs 0.000 description 12
- 235000010323 ascorbic acid Nutrition 0.000 description 12
- 239000011668 ascorbic acid Substances 0.000 description 12
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 11
- 239000010452 phosphate Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 210000004100 adrenal gland Anatomy 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000000654 additive Substances 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000000996 additive effect Effects 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 229920000388 Polyphosphate Polymers 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- -1 nucleoside phosphates Chemical class 0.000 description 4
- 239000001205 polyphosphate Substances 0.000 description 4
- 235000011176 polyphosphates Nutrition 0.000 description 4
- 230000001919 adrenal effect Effects 0.000 description 3
- 235000011180 diphosphates Nutrition 0.000 description 3
- 235000011007 phosphoric acid Nutrition 0.000 description 3
- 229940048084 pyrophosphate Drugs 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- LRXTYHSAJDENHV-UHFFFAOYSA-H zinc phosphate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O LRXTYHSAJDENHV-UHFFFAOYSA-H 0.000 description 3
- 229940077935 zinc phosphate Drugs 0.000 description 3
- 229910000165 zinc phosphate Inorganic materials 0.000 description 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- HXXFSFRBOHSIMQ-VFUOTHLCSA-N alpha-D-glucose 1-phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(O)=O)[C@H](O)[C@@H](O)[C@@H]1O HXXFSFRBOHSIMQ-VFUOTHLCSA-N 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229950010772 glucose-1-phosphate Drugs 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 150000003014 phosphoric acid esters Chemical class 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical class OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 229910021503 Cobalt(II) hydroxide Inorganic materials 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical group [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101150107341 RERE gene Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 108010071339 adrenocorticotropin zinc Proteins 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical group 0.000 description 1
- CVSVTCORWBXHQV-UHFFFAOYSA-N anhydrous creatine Natural products NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940118821 benzyl alcohol 20 mg/ml Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- ASKVAEGIVYSGNY-UHFFFAOYSA-L cobalt(ii) hydroxide Chemical compound [OH-].[OH-].[Co+2] ASKVAEGIVYSGNY-UHFFFAOYSA-L 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N glycerol 1-phosphate Chemical class OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 150000004692 metal hydroxides Chemical class 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- BFDHFSHZJLFAMC-UHFFFAOYSA-L nickel(ii) hydroxide Chemical compound [OH-].[OH-].[Ni+2] BFDHFSHZJLFAMC-UHFFFAOYSA-L 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 150000002903 organophosphorus compounds Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- HCTVWSOKIJULET-LQDWTQKMSA-M phenoxymethylpenicillin potassium Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)COC1=CC=CC=C1 HCTVWSOKIJULET-LQDWTQKMSA-M 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 150000003018 phosphorus compounds Chemical class 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 239000011591 potassium Chemical group 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940005657 pyrophosphoric acid Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 150000003752 zinc compounds Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- A61K38/35—Corticotropin [ACTH]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL268104 | 1961-08-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE1210126B true DE1210126B (de) | 1966-02-03 |
Family
ID=19753222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DEN21945A Pending DE1210126B (de) | 1961-08-10 | 1962-08-10 | Verfahren zur Stabilisierung von langwirkenden Suspensionen von adrenokortikotropem Hormon (ACTH) |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US3243345A (en:Method) |
| CH (1) | CH433593A (en:Method) |
| DE (1) | DE1210126B (en:Method) |
| FR (1) | FR2340M (en:Method) |
| GB (1) | GB977836A (en:Method) |
| NL (1) | NL268104A (en:Method) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL289055A (en:Method) * | 1963-02-15 | |||
| JPS6028999A (ja) * | 1983-06-30 | 1985-02-14 | Maruho Kk | 細胞増殖促進作用を有するたんぱく質、その組成物と製造方法 |
| ZA201407536B (en) | 2013-10-21 | 2017-09-27 | Ems Sa | Parenteral pharmaceutical composition containing cosyntropin |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL81943C (en:Method) * | 1900-01-01 | |||
| GB757934A (en) * | 1953-01-17 | 1956-09-26 | Organon Labor Ltd | New adrenocorticotrophic hormone preparations and processes for making same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2734016A (en) * | 1956-02-07 | Protamine zinc adrenocorticotrophin | ||
| US2807569A (en) * | 1953-01-17 | 1957-09-24 | Organon | Adrenocorticotropic hormone composition |
| US2902408A (en) * | 1957-09-12 | 1959-09-01 | Organon | Suspensions of drugs destined for injection and process for the preparation thereof |
-
0
- NL NL268104D patent/NL268104A/xx unknown
-
1962
- 1962-07-25 US US212454A patent/US3243345A/en not_active Expired - Lifetime
- 1962-07-27 GB GB28956/62A patent/GB977836A/en not_active Expired
- 1962-08-06 CH CH936762A patent/CH433593A/de unknown
- 1962-08-10 DE DEN21945A patent/DE1210126B/de active Pending
- 1962-11-08 FR FR906412A patent/FR2340M/fr active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL81943C (en:Method) * | 1900-01-01 | |||
| GB757934A (en) * | 1953-01-17 | 1956-09-26 | Organon Labor Ltd | New adrenocorticotrophic hormone preparations and processes for making same |
Also Published As
| Publication number | Publication date |
|---|---|
| CH433593A (de) | 1967-04-15 |
| NL268104A (en:Method) | |
| GB977836A (en) | 1964-12-16 |
| US3243345A (en) | 1966-03-29 |
| FR2340M (fr) | 1964-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69708121T3 (de) | Halogenid-enthaltende insulinzubereitungen | |
| DE2219635C3 (de) | Insulinsalz-Protamin-Komplexe und Verfahren zu ihrer Herstellung | |
| DE2506579A1 (de) | Oxytetracyclinloesung zur parenteralen, peroralen und lokalen anwendung und verfahren zu deren herstellung | |
| EP0291863A2 (de) | Mischkristalle aus Insulin und Insulinderivaten, Verfahren zur Herstellung dieser Mischkristalle und diese Mischkristalle enthaltende pharmazeutische Mittel | |
| DE2855851C2 (de) | Stabilisierte Addukte von Vitamin-K-Verbindungen mit organischen Verbindungen, Verfahren zu deren Herstellung und deren Verwendung | |
| DE69625200T2 (de) | Arzneimittel enthaltend lamotrigin | |
| DE69002697T2 (de) | Carboplatinzusammensetzung. | |
| DE2515001C2 (de) | Prostaglandin enthaltende gefriergetrocknete Pulver | |
| DE1210126B (de) | Verfahren zur Stabilisierung von langwirkenden Suspensionen von adrenokortikotropem Hormon (ACTH) | |
| DE3119510C2 (en:Method) | ||
| DE3014223A1 (de) | Oxytetracyclin-arzneimittel | |
| AT401469B (de) | Pharmazeutische wässrige lösung zur parenteralen anwendung enthaltend einen in situ gebildeten komplex von einem alkaloid mit bis-indol-gerüst, sowie verfahren zu deren herstellung | |
| DE1212679B (de) | Verfahren zur Herstellung von Insulinloesungen | |
| DE1518057C3 (de) | Injizierbares adrenocorticotropes Hormonpräparat mit prolongierter ACTH-Aktivität | |
| DE2117014A1 (de) | Salze der Jodmethansulfonsaure mit organischen Basen | |
| WO2002026233B1 (de) | Lagerstabile infusionslösung des ciprofloxacins mit verringertem säuregehalt | |
| DE2437145A1 (de) | Ein corticosteroid-phosphatsalz und neomycin-sulfat enthaltende waessrige loesung | |
| DE1667900B2 (de) | Schnell wirkende, beständige Rinderinsulinlösung | |
| DE2716535A1 (de) | Mittel zum schutz vor nierenversagen | |
| DE2950832C2 (de) | Spritzfertige injizierbare wäßrige Lösungen der Alkalisalze von Canrenoinsäure und Furosemid | |
| DE2731013C2 (de) | Verfahren zur Herstellung einer wäßrigen Infusionslösung | |
| DE1190140B (de) | Verfahren zur Herstellung von ACTH-Praeparaten | |
| DE977478C (de) | Verfahren zur Herstellung injizierbarer Insulinpraeparate mit verzoegerter Wirkung | |
| DE2512943A1 (de) | Verfahren zur herstellung protrahiert wirksamer injektionspraeparate | |
| AT201233B (de) | Verfahren zur Herstellung von zur Injektion geeigneten Präparaten des adrenocorticotropen Hormons mit erhöhter und verlängerter Wirksamkeit |